Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings PLC is strategically positioned for growth through its innovative ImmTAX platform, with multiple therapeutic programs in oncology, infectious disease, and autoimmune conditions, supporting a robust pipeline that enhances its long-term revenue potential. The company's flagship product, KIMMTRAK, has consistently surpassed quarterly sales consensus in the majority of its launch period, demonstrating strong market demand and performance, particularly in the treatment of unresectable or metastatic uveal melanoma. Furthermore, while U.S. market penetration appears to be stabilizing, future revenue growth is anticipated from expanded international launches and improved treatment duration, indicating a solid foundation for sustained commercial expansion.

Bears say

Immunocore Holdings faces significant financial risks due to underwhelming clinical data from key melanoma trials, with reported overall response rates of only 11% and 6% for monotherapy treatments, which fell short of market expectations. Additionally, emerging competition from IDYA’s darovasertib poses a threat to KIMMTRAK's market potential in the HLA-A2+ mUM segment, with expected updates that could negatively impact the company's market share. Coupled with potential research and development setbacks, regulatory challenges, and the risk of dilutive financing, these factors contribute to a negative outlook for Immunocore Holdings's stock.

Immunocore Holdings (IMCR) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 9 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.